Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

Medicine & Life Sciences

• Fedratinib 100%
• Janus Kinase 2 72%
• Janus Kinase Inhibitors 72%
• Primary Myelofibrosis 64%
• Safety 30%
• Anemia 8%
• Alleles 7%
• Essential Thrombocythemia 6%
• Thrombocytosis 6%
• Polycythemia Vera 6%
• Sweat 6%
• Maximum Tolerated Dose 6%
• Mutation 5%
• Splenomegaly 5%
• Amylases 5%
• Leukocytosis 5%
• Pruritus 5%
• Cough 4%
• Thrombocytopenia 4%
• Serum 4%
• Nausea 4%
• Vomiting 4%
• Fatigue 4%
• Diarrhea 4%
• Spleen 4%
• Cytokines 3%
• Therapeutics 2%
• Incidence 2%
• Neoplasms 1%